5 unchanged sentences
10-K 001-37752 3.1 3/15/2018
−Removed: Certificate of Amendment to the Certificate of Incorporation of the Registrant
+Added: 3.2 Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation
8-K 000-53290 3.1 3/19/2025
−Removed: Amended and Restated Bylaws of the Registrant
+Added: 3.3 Amended and Restated Bylaws of Niagen Bioscience, Inc.
8-K 000-53290 3.1 3/19/2025
−Removed: Offer Letter, dated September 10, 2024, by and between Ozan Pamir and ChromaDex, Inc.
+Added: 4.1 Form of Stock Certificate representing shares of the Registrant’s Common Stock
+Added: Amendment to Amended and Restated Executive Employment Agreement, dated February 25, 2025, by and between Robert Fried and the Registrant
8-K 001-37752 10.1 2/27/2025
−Removed: Tenth Amendment to Manufacturing and Supply Agreement, dated as of January 1, 2025, by and between ChromaDex Inc.
−Removed: Grace & Co.-Conn.**
+Added: 10.2 Performance Stock Unit Award Agreement, dated February 25, 2025, by and between Robert Fried and the Registrant
+Added: 8-K 001-37752 10.2 2/27/2025
+Added: 10.3 Second Amendment to Lease Agreement, dated March 11, 2025, by and between ChromaDex Analytics, Inc.
+Added: and 62 1625-1751 S.
+Added: Fordham LLC and 64 1625-1751 S.
+Added: 10.4 Seventh Modification to Business Financing Agreement dated March 24, 2025 by and among Western Alliance Bank, Niagen Bioscience, Inc., ChromaDex Inc.
+Added: and ChromaDex Analytics, Inc.
+Added: 10.5 Niagen Bioscience, Inc.
+Added: 2017 Equity Incentive Plan, as amended
+Added: 10.6 Form of Stock Option Agreement under Niagen Bioscience, Inc.
+Added: 2017 Equity Incentive Plan, as amended
+Added: 10.7 Form of Restricted Stock Purchase Agreement under the Niagen Bioscience, Inc.
+Added: 2017 Equity Incentive Plan, as amended
+Added: 10.8 Amended and Restated Non-Employee Director Compensation Policy
+Added: 10.9 Amended and Restated Incentive Compensation Recoupment Policy
Certification of the Chief Executive Officer pursuant to Rule 13a-14(A) of the Securities Exchange Act of 1934, as amended
9 unchanged sentences
104 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
−Removed: ** Certain portions of this exhibit are omitted because they are both not material and are the type that the Registrant treats as private or confidential.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: CHROMADEX CORPORATION
−Removed: October 31, 2024 /s/ OZAN PAMIR
+Added: NIAGEN BIOSCIENCE, INC.
+Added: May 7, 2025 /s/ OZAN PAMIR
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.